{"id":420209,"date":"2021-01-25T08:33:18","date_gmt":"2021-01-25T13:33:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=420209"},"modified":"2021-01-25T08:33:18","modified_gmt":"2021-01-25T13:33:18","slug":"alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/","title":{"rendered":"Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>AL002 is the first product candidate targeting TREM2 in Phase 2 clinical development<\/em>\n        <\/li>\n<li>\n          <em>Study will enroll early Alzheimer\u2019s disease patients at up to 90 sites globally<\/em>\n        <\/li>\n<li>\n          <em>Alzheimer\u2019s disease is a devastating neurological disease affecting nearly six million people in the U.S. and 35 million globally<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p>SOUTH SAN FRANCISCO, Calif., Jan.  25, 2021  (GLOBE NEWSWIRE) &#8212; Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in INVOKE-2, a Phase 2 clinical study evaluating the efficacy and safety of AL002 in slowing disease progression in individuals with early Alzheimer\u2019s disease. AL002 is an investigational, humanized monoclonal antibody that targets triggering receptor expressed on myeloid cells 2 (TREM2), a transmembrane receptor protein that is expressed on a subset of innate immune cells and selectively on microglia, which serve as the immune cells in the brain. The AL002 clinical program is being developed in collaboration with AbbVie.<\/p>\n<p>The role of TREM2 in Alzheimer\u2019s disease was first discovered through large scale genome-wide association studies where it has been shown to have one of the most important genetic links to sporadic Alzheimer\u2019s disease. Research suggests that reduction of TREM2 functionality may lead to Alzheimer&#8217;s disease and other forms of dementia. Increasing TREM2 activity in the brain may prove to be an effective therapeutic approach by activating the brain\u2019s immune system to target multiple pathologies that are present in Alzheimer\u2019s disease, rather than focusing on a single pathology.<\/p>\n<p>\u201cLoss of TREM2 activity has been shown through human genetics to be one of the notable risk factors for developing Alzheimer\u2019s disease,\u201d said\u00a0Robert Paul, M.D., Ph.D., chief medical officer of\u00a0Alector. \u201cAL002 is a first-in-class TREM2 targeting antibody in Phase 2 clinical development for Alzheimer\u2019s disease. By targeting this receptor, we believe it may be possible to slow the progression of this disease. Our ability to move quickly into a Phase 2 study is based on compelling preclinical and Phase 1 data showing that AL002 engages TREM2 on microglia cells in the brain, resulting in increased microglial activity. We look forward to efficiently enrolling the Phase 2 study to better understand the potential clinical benefits of AL002.\u201d<\/p>\n<p>\u201cAlzheimer\u2019s is a devastating disease that robs a person of their identity, and a family of their loved one. We are hopeful that AL002 may one day be a treatment option for the millions of people diagnosed with this disease,\u201d said Michael Gold, M.D., vice president, Development Neurosciences, AbbVie. \u201cWe are pleased that the study was initiated rapidly and look forward to data from the Phase 2 study that will inform a potential pivotal clinical development program for AL002.\u201d<\/p>\n<p>INVOKE-2 is a randomized, double-blind, placebo-controlled, dose-ranging, multi-center Phase 2 study that will enroll approximately 265 participants with early Alzheimer\u2019s disease at up to 90 sites globally. The primary endpoint of the Phase 2 study is to measure disease progression utilizing the Clinical Dementia Rating Sum Boxes (CDR-SB). The CDR-SB is a validated instrument that assess both cognitive and functional domains and is used to assess (score) the severity of Alzheimer\u2019s disease. The study will also employ multiple fluid and imaging biomarkers, and will assess several secondary clinical, pharmacokinetic and pharmacodynamic endpoints, as well as the safety of treatment with AL002.<\/p>\n<p>To learn more about the Phase 2 study, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JxGFelBpTCJwuy6hmjunsBbZBOq7tWbgS7SmH9jCDTXRDd_gKUfI5wef8Zebu0QKhvinxRcSaJrrw0fn3DHLxBHaRu0TJnv5-JYcgvKAxn4WsVWSstq6WVOhM4gBN_Px6t3pwF-qnM5vV-sJ7cIGTH7XtGMOb9bFyR36F0FHnxM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/clinicaltrials.gov\/<\/a>.<\/p>\n<p>\n        <strong>About AL002<\/strong><br \/>\n        <br \/>AL002 is an investigational humanized monoclonal antibody that targets triggering receptor expressed on myeloid cells 2 (TREM2) with the most important genetic links to sporadic Alzheimer\u2019s disease. TREM2 is a transmembrane receptor expressed on a subset of innate immune cells and selectively on microglia, which constitute the brain\u2019s immune system. Reduction of TREM2 functionality may lead to Alzheimer&#8217;s disease and other forms of dementia. AL002 counteracts this decreased functionality by optimizing TREM2 signaling to improve cell survival and proliferation, and activity of microglia.<\/p>\n<p>\n        <strong>Collaboration with AbbVie<\/strong><br \/>\n        <br \/>In October 2017, Alector entered into a global strategic collaboration with AbbVie (NYSE: ABBV), to co-develop and commercialize therapeutics to treat Alzheimer\u2019s disease and other neurodegenerative diseases. Under the terms of the agreement, Alector granted AbbVie an exclusive option to global development and commercialization for two programs, including TREM2. Following AbbVie\u2019s exercise of its option for either program (or both), Alector is eligible for additional option exercise and milestone payments totaling up to $986M. Both companies will share the development costs and will split global profits equally after marketing approval.<\/p>\n<p><strong>About Alzheimer\u2019s Disease<\/strong><br \/>Alzheimer\u2019s disease is a degenerative brain disease and the most common form of dementia. It is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability of patients to care for themselves. In most people with Alzheimer\u2019s disease, symptoms first appear in their mid-60s. The Alzheimer\u2019s Association estimates that as of 2020, there are 5.8 million Americans aged 65 and older living with Alzheimer\u2019s disease, and projects that number will rise to nearly 14 million by 2050.<\/p>\n<p><strong>About\u00a0Alector<\/strong><br \/>Alector\u00a0is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company\u00a0is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain\u2019s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.\u00a0The Company\u2019s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer\u2019s disease. This scientific approach is also the basis for the Company\u2019s immuno-oncology programs.\u00a0Alector\u00a0is headquartered in\u00a0South\u00a0San Francisco, California. For additional information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T0x-W6eXkdhJ97Ly4C5KXBc5mYojmnmN6QB5vzr_Uz01yd22606D80RcpieccpwIo7UoSQrZ0KOKsX9hJXsodA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.alector.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to risks and uncertainties related to the Company\u2019s plans for and anticipated benefits and mechanism of the Company\u2019s product candidates, the timing and objectives of the Company\u2019s clinical studies and anticipated regulatory and development milestones, and Alector and its business as set forth in Alector\u2019s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on November 10, 2020, as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector\u2019s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.<\/p>\n<p>\n        <strong>Contacts: <\/strong>\n      <\/p>\n<p>Media <br \/>Erica Jefferson<br \/>Vice President, Communications and Public Affairs<br \/>Alector, Inc.<br \/>301-928-4650<br \/>erica.jefferson@alector.com<\/p>\n<p>1AB <br \/>Dan Budwick<br \/>973-271-6085 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2JJCP5ErIjzkIUPWsoeQNMbOvY5Z-xpTQKJ8LnDeR3iAsOyTJB41BeTjLBs9k1zkqL9FlfN3TGQkYx0uIcWZeg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">dan@1abmedia.com<\/a><br \/>or<\/p>\n<p>Investors: <br \/>Alector, Inc. <br \/>ir@alector.com<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDcwOSMzOTQxNzUzIzIxMjQ5OTA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/dc421917-8805-47de-a3d4-9a0a62cf6751\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AL002 is the first product candidate targeting TREM2 in Phase 2 clinical development Study will enroll early Alzheimer\u2019s disease patients at up to 90 sites globally Alzheimer\u2019s disease is a devastating neurological disease affecting nearly six million people in the U.S. and 35 million globally SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) &#8212; Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in INVOKE-2, a Phase 2 clinical study evaluating the efficacy and safety of AL002 in slowing disease progression in individuals with early Alzheimer\u2019s disease. AL002 is an investigational, humanized monoclonal antibody that targets triggering receptor expressed on myeloid cells 2 (TREM2), a transmembrane receptor protein that &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-420209","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AL002 is the first product candidate targeting TREM2 in Phase 2 clinical development Study will enroll early Alzheimer\u2019s disease patients at up to 90 sites globally Alzheimer\u2019s disease is a devastating neurological disease affecting nearly six million people in the U.S. and 35 million globally SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) &#8212; Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in INVOKE-2, a Phase 2 clinical study evaluating the efficacy and safety of AL002 in slowing disease progression in individuals with early Alzheimer\u2019s disease. AL002 is an investigational, humanized monoclonal antibody that targets triggering receptor expressed on myeloid cells 2 (TREM2), a transmembrane receptor protein that &hellip; Continue reading &quot;Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-25T13:33:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDcwOSMzOTQxNzUzIzIxMjQ5OTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease\",\"datePublished\":\"2021-01-25T13:33:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\\\/\"},\"wordCount\":1183,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDcwOSMzOTQxNzUzIzIxMjQ5OTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\\\/\",\"name\":\"Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDcwOSMzOTQxNzUzIzIxMjQ5OTA=\",\"datePublished\":\"2021-01-25T13:33:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDcwOSMzOTQxNzUzIzIxMjQ5OTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MDcwOSMzOTQxNzUzIzIxMjQ5OTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease - Market Newsdesk","og_description":"AL002 is the first product candidate targeting TREM2 in Phase 2 clinical development Study will enroll early Alzheimer\u2019s disease patients at up to 90 sites globally Alzheimer\u2019s disease is a devastating neurological disease affecting nearly six million people in the U.S. and 35 million globally SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) &#8212; Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in INVOKE-2, a Phase 2 clinical study evaluating the efficacy and safety of AL002 in slowing disease progression in individuals with early Alzheimer\u2019s disease. AL002 is an investigational, humanized monoclonal antibody that targets triggering receptor expressed on myeloid cells 2 (TREM2), a transmembrane receptor protein that &hellip; Continue reading \"Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-25T13:33:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDcwOSMzOTQxNzUzIzIxMjQ5OTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease","datePublished":"2021-01-25T13:33:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/"},"wordCount":1183,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDcwOSMzOTQxNzUzIzIxMjQ5OTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/","name":"Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDcwOSMzOTQxNzUzIzIxMjQ5OTA=","datePublished":"2021-01-25T13:33:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDcwOSMzOTQxNzUzIzIxMjQ5OTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MDcwOSMzOTQxNzUzIzIxMjQ5OTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alector-announces-first-participant-dosed-in-phase-2-study-evaluating-al002-in-individuals-with-early-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/420209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=420209"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/420209\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=420209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=420209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=420209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}